Experts' considerations on HLA-haploidentical stem cell transplantation

European Journal of Haematology

Volumn 93, Issue 3, 2014, Pages 187-197

  Patriarca, Francesca ^a   Luznik, Leo ^b   Medeot, Marta ^a   Zecca, Marco ^c   Bacigalupo, Andrea ^d   Di Bartolomeo, Paolo ^e   Arcese, William ^f   Corradini, Paolo ^g   Ciceri, Fabio ^h   Vago, Luca ^h   Kanakry, Christopher G ^b   Fleischhauer, Katharina ^h   Martelli, Massimo F ⁱ   Bosi, Alberto ^j   Rambaldi, Alessandro ^k   Cesaro, Simone ^l   Russo, Domenico ^m   Fanin, Renato ^a  

^a UNIVERSITY HOSPITAL OF UDINE   (Italy)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e SPIRITO SANTO HOSPITAL   (Italy)

^f UNIVERSITY OF ROME TOR VERGATA   (Italy)

^g NATIONAL CANCER INSTITUTE   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j UNIVERSITY OF FLORENCE   (Italy)

^k PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^l Policlinico GB Rossi   (Italy)

^m UNIVERSITY OF BRESCIA   (Italy)

more..

Author keywords

Allogeneic stem cell transplantation; HLA haploidentical donors; Post transplantation cyclophosphamide; T cell depletion

Indexed keywords

BLOOD GROUP ABO SYSTEM; HLA ANTIGEN; IMMUNOSUPPRESSIVE AGENT; MYELOABLATIVE AGENT;

ADOPTIVE IMMUNOTHERAPY; ALLOTRANSPLANTATION; BLOOD GROUP ABO SYSTEM; CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TEST; HUMAN; IMMUNOLOGY; LYMPHOCYTE DEPLETION; ORGANIZATION; PATHOLOGY; PATIENT SELECTION; TIME FACTOR; TRANSPLANTATION CONDITIONING; UNRELATED DONORS;

ABO BLOOD-GROUP SYSTEM; CONGRESSES AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HISTOCOMPATIBILITY TESTING; HLA ANTIGENS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE DEPLETION; MYELOABLATIVE AGONISTS; PATIENT SELECTION; TIME FACTORS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; UNRELATED DONORS;

EID: 84906086309     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12322     Document Type: Article

References (83)

1. Buckner CD, Epstein RB, Rudolph RH, Clift RA, Storb R, Thomas ED. Allogeneic marrow engraftment following whole body irradiation in a patient with leukemia. Blood 1970;35:741-50.
2. Clift RA, Hansen JA, Thomas ED, Buckner CD, Sanders JE, Mickelson EM, Storb R, Johnson FL, Singer JW, Goodell BW. Marrow transplantation from donors other than HLA-identical siblings. Transplantation 1979;28:235-42.
3. Powles RL, Morgenstern GR, Kay HE, et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983;1:612-5.
4. Beatty PG, Clift RA, Mickelson EM, et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985;313:765-71.
5. Szydlo R, Goldman JM, Klein JP, et al. Results of allogeneic bone marrow transplants for leukemia using donors other than HLA identical siblings. J Clin Oncol 1997;15:1767-77.
6. Kernan NA, Flomenberg N, Dupont B, O'Reilly RJ. Graft rejection in recipients of T-cell-depleted HLA-nonidentical marrow transplants for leukemia: identification of host-derived antidonor allocytotoxic T lymphocytes. Transplantation 1987;43:842-7.
7. Soiffer RJ, Mauch P, Tarbell NJ, et al. Total lymphoid irradiation to prevent graft rejection in recipients of HLA non-identical T cell-depleted allogeneic marrow. Bone Marrow Transplant 1991;7:23-33.
8. Gale RP, Reisner Y. Graft rejection and graft-versus-host disease: mirror images. Lancet 1986;1:1468-70.
9. Martin PJ. The role of donor lymphoid cells in allogeneic marrow engraftment. Bone Marrow Transplant 1990;6:283-9.
10. Aversa F, Tabilio A, Terenzi A, Velardi A, Falzetti F, Giannoni C, Iacucci R, Zei T, Martelli MP, Gambelunghe C. Successful engraftment of T-cell depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1994;84:3948-55.
11. Aversa F, Tabilio A, Velardi A, et al. Treatment of high risk leukemia with T cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998;339:1186-93.
12. Aversa F, Terenzi A, Tabilio A, et al. Full-haplotype mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse. J Clin Oncol 2005;23:3447-54.
13. Ruggeri L, Mancusi A, Capanni M, et al. Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value. Blood 2007;110:433-40.
14. Nguyen VH, Zeiser R, daSilva DL, Chang DS, Beilhack A, Contag CH, Negrin RS. In vivo dynamics of regulatory T-cell trafficking and survival predict effective strategies to control graft-versus-host disease following allogeneic transplantation. Blood 2007;109:2649-56.
15. Di Ianni M, Falzetti F, Carotti A, et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011;117:3921-8.
16. De Lalla C, Rinaldi A, Montagna D, et al. Invariant NKT cell reconstitution in pediatric leukemia patients given HLA-haploidentical stem cell transplantation defines distinct CD4+ and CD4- subset dynamics and correlates with remission state. J Immunol 2011;186:4490-9.
17. Clave E, Lisini D, Douay C, Giorgiani G, Busson M, Zecca M, Charron D, Bernardo ME, Toubert A, Locatelli F. A low thymic function is associated with leukemia relapse in children given T-cell-depleted HLA-haploidentical stem cell transplantation. Leukemia 2012;26:1886-8.
18. Comoli P, Basso S, Zecca M, et al. Preemptive therapy of EBV-related lymphoproliferative disease after pediatric haploidentical stem cell transplantation. Am J Transplant 2007;7:1648-55.
19. Comoli P, Basso S, Labirio M, Baldanti F, Maccario R, Locatelli F. T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant. Blood Cells Mol Dis 2008;40:68-70.
20. Comoli P, Schilham MW, Basso S, van Vreeswijk T, Bernardo ME, Maccario R, van Tol MJ, Locatelli F, Veltrop-Duits LA. T-cell lines specific for peptides of adenovirus hexon protein and devoid of alloreactivity against recipient cells can be obtained from HLA-haploidentical donors. J Immunother 2008;31:529-36.
21. Comoli P, Zecca M, Maccario R. Immunotherapy against EBV-lymphoma in recipients of HSCT. Expert Rev Hematol 2010;3:625-32.
22. Rizzieri DA, Koh LP, Long GD, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol 2007;25:690-7.
23. Dodero A, Carniti C, Raganato A, et al. Haploidentical stem cell transplantation after reduce-intensity conditioning regimen for the treatment of advanced hematological malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T -cell recovery. Blood 2009;113:4771-9.
24. Giralt S, Hester J, Huh Y, et al. CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. Blood 1995;86:4337-43.
25. Soiffer RJ, Alyea EP, Hochberg EP, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J. Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion. Biol Blood Marrow Transplant 2002;8:625-32.
26. Alyea EP, Canning C, Neuberg D, Daley H, Houde H, Giralt S, Champlin R, Atkinson K, Soiffer RJ. CD8_cell depletion of donor lymphocyte infusions using CD8 monoclonal antibody-coated highdensity microparticles (CD8-HDM) after allogeneic hematopoietic stem cell transplantation: a pilot study. Bone Marrow Transplant 2004;34:123-8.
27. Meyer RG, Britten CM, Wehler D, et al. Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation. Blood 2007;109:374-82.
28. Zheng H, Matte-Martone C, Li H, Anderson BE, Venketesan S, Sheng Tan H, Jain D, McNiff J, Shlomchik WD. Effector memory CD4_ T cells mediate graft-versus leukemia without inducing graft-versus-host disease. Blood 2008;111:2476-84.
29. Berenbaum MC, Brown IN. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963;200:84.
30. Mayumi H, Umesue M, Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiology 1996;195:129-39.
31. Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001;98:3456-64.
32. Luznik L, Engstrom LW, Iannone R, Fuchs EJ. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002;8:131-8.
33. Luznik L, Jones RJ, Fuchs EJ. High-dose cyclophpsphamide for graft-versus-host-disease prevention. Curr Opin Hematol 2010;17:493-9.
34. Eto M, Mayumi H, Tomita Y, Yoshikai Y, Nishimura Y, Maeda T, Ando T, Nomoto K. Specific destruction of host-reactive mature T cells of donor origin prevents graft-versus-host disease in cyclophosphamide-induced tolerant mice. J Immunol 1991;146:1402-9.
35. Gibbons C, Sykes M. Manipulating the immune system for anti-tumor responses and transplant tolerance via mixed hematopoietic chimerism. Immunol Rev 2008;223:334-60.
36. Ganguly S, Fuchs EJ, Radojcic V, Luznik L. Critical role of CD4_Foxp3 T cells in GVHD prevention with high dose posttransplantation cyclophosphamide (Cy). Blood 2010; 116: abstract 3749.
37. Kanakry CG, Ganguly S, Zahurak M, Bolaños-Meade J, Thoburn C, Perkins B, Fuchs EJ, Jones RJ, Hess AD, Luznik L. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med 2013;211; doi: 10.1126/scitranslmed.3006960.
38. O'Donnell PV, Luznik L, Jones RJ, Vogelsang GB, Leffell MS, Phelps M, Rhubart P, Cowan K, Piantados S, Fuchs EJ. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2002;8:377-86.
39. Luznik L, O'Donnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for haematological malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008;14:641-50.
40. Munchel A, Kesserwan C, Symons HJ, Luznik L, Kasamon YL, Jones RJ, Fuchs EJ. Nonmyeloablative, HLA-Haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011;3(Suppl 2):e15.
41. Kasamon YL, Luznik L, Leffell MS, et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose post-transplant cyclophospamide: effect of HLA disparity on outcome. Biol Bone Marrow Transplant 2010;16:533-42.
42. Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or related double umbilical cord blood grafts. Blood 2011;118:282-8.
43. Bolanos-Meade J, Fuchs EJ, Luznik L, Lanzkron S, Gamper CJ, Jones RJ, Brodsky RA. HLA-haploidentical bone marrow transplantation with posttransplant cyclophosphamide expands the donor pool for patients with sickle cell disease. Blood 2012;120:4285-91.
44. Grosso D, Carabasi M, Filicko-O'Hara J, et al. A 2-step approach to myeloablative haploidentical stem cell transplantation: a phase 1/2 trial performed with optimized T-cell dosing. Blood 2011;118:4732-9.
45. Ciurea SO, Mulanovich V, Saliba RM, et al. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical haematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2012;18:1835-44.
46. Bashey A, Zhang X, Sizemore CA, Manion K, Brown S, Holland HK, Morris LE, Solomon SR. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013;31:1310-6.
47. Sanz J, Boluda JC, Martin C, et al. Single-unit umbilical cord blood transplantation from unrelated donors in patients with hematological malignancy using busulfan, thiotepa, fludarabine and ATG as myeloablative conditioning regimen. Bone Marrow Transplant 2012;47:1287-93.
48. Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013;19:117-22.
49. + cell count and transplant-related mortality. Bone Marrow Transplant 2008;41:55-62.
50. Raiola AM, Ghiso A, Dominietto A, et al. Post-transplant cyclophosphamide following a myeloablative conditioning for hematologic malignancies receiving an unmanipulated haploidentical bone marrow transplant. Blood 2013;122:abstract 2103.
51. Peccatori J, Clerici D, Forcina A, et al. In-vivo T-regs generation by rapamycin-mycophenolate-ATG as a new platform for GVHD prophylaxis in T-cell repleted unmanipulated haploidentical peripheral stem cell transplantation: results in 59 patients. Bone Marrow Transplant 2010;45(Suppl 2):S3 (abstract 88).
52. Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG. Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol 2006;177:8338-47.
53. Teachey DT, Grupp SA, Brown VI. Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies. Br J Haematol 2009;145:569-80.
54. Vago L, Perna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med 2009;361:478-88.
55. Vago L, Forno B, Sormani MP, et al. Temporal, quantitative, and functional characteristics of single-KIR-positive alloreactive natural killer cell recovery account for impaired graft-versus-leukemia activity after haploidentical hematopoietic stem cell transplantation. Blood 2008;112:3488-99.
56. Wang Y, Liu DH, Liu KY, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer 2013;119:978-85.
57. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using granulocyte colony-stimulating factor. Haematologica 2004;89:1517-24.
58. Di Bartolomeo P, Santarone S, De Angelis G, et al. Haploidentical, unmanipulated, G-CSF-primed bone marrow transplantation for patients with high-risk hematologic malignancies. Blood 2013;121:849-57.
59. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcome with HLA-identical sibling transplantation. Blood 2006;107:3065-73.
60. Burroughs LM, O'Donnell PV, Sandmaier BM, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transplant 2008;14:1279-87.
61. Xiao-Jun T, Lan-Ping X, Kai-Yan L, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res 2009;15:4777-83.
62. Anasetti C, Beatty PG, Storb R, Martin PJ, Mori M, Sanders JE, Thomas ED, Hansen JA. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990;29:79-91.
63. Kawase T, Morishima Y, Matsuo K, Kashiwase K, Inoko H, Saji H, Kato S, Juji T, Kodera Y, Sasazuki T. Japan Marrow Donor Program. High-risk HLA allele mismatch combinations responsible for severe acute graft-versus-host disease and implications for its molecular mechanism. Blood 2007;110:2235-41.
64. Kanda Y, Chiba S, Hirai H, et al. Allogeneic hematopoietic stem cell transplantation from family members other than HLA identical siblings over the last decade (1991-2000). Blood 2003;102:1541-7.
65. Petersdorf EW, Gooley TA, Anasetti C, Martin PJ, Smith AG, Mickelson EM, Woolfrey AE, Hansen JA. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient. Blood 1998;92:3515-20.
66. Morishima Y, Yabe T, Matsuo K, et al. Japan Marrow Donor Program. Effects of HLA allele and killer immunoglobulin-like receptor ligand matching on clinical outcome in leukemia patients undergoing transplantation with T cell-replete marrow from an unrelated donor. Biol Blood Marrow Transplant 2007;13:315-28.
67. Huang XJ, Zhao XY, Liu DH, Liu KY, Xu LP. Deleterius effect of KIR ligand incompatibility on clinical outcomes in haploidentical hematopietic stem cell transplantation without in vitro T-cell depletion. Leukemia 2007;21:848-51.
68. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood 2008;112:3574-81.
69. Pende D, Marcenaro S, Falco M, et al. Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity. Blood 2009;113:3119-29.
70. Symons HJ, Leffell MS, Rossiter ND, Zahurak M, Jones RJ, Fuchs EJ. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatched and KIR haplotype B donors after HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant 2010;16:533-42.
71. Loren AW, Bunin GR, Boudreau C, Champlin RE, Cnaan A, Horowitz MM, Loberiza FR, Porter DL. Impact of donor and recipient sex and parity on outcomes of HLA-sibling allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006;12:758-69.
72. van Rood JJ, Loberiza FR Jr, Zhang MJ, et al. Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. Blood 2002;99:1572-7.
73. Ichinohe T, Uchiyama T, Shimazaki C, et al. Japanese Collaborative Study Group for NIMA-Complementary Haploidentical Stem Cell Transplantation. Feasibility of HLA-haploidentical hematopoietic stem cell transplantation between noninherited maternal antigen (NIMA)-mismatched family members linked with long-term fetomaternal microchimerism. Blood 2004;104:3821-8.
74. Stern M, Ruggeri L, Mancusi A, Bernardo ME, de Angelis C, Bucher C, Locatelli F, Aversa F, Velardi A. Survival after T cell-depleted haploidentical stem cell transplantation is improved using the mother as donor. Blood 2008;112:2990-5.
75. Yoshihara S, Maruya E, Taniguchi K, et al. Risk and prevention of graft failure in patients with preexsisting HLA antibodies undergoing unmanipulated haploidentical SCT. Bone Marrow Transplant 2012;47:508-12.
76. Gladstone DE, Zachary AA, Fuchs EJ, Luznik L, Kasamon YL, King KE, Brodsky RA, Jones RJ, Leffell MS. Partially mismatched transplantation and human leukocyte antigen donor-specific antibodies. Biol Blood Marrow Transplant 2013;19:647-52.
77. Symons H, Chen AR, Luznik L, Kasamon YL, Bolanos Meade J, Jones RJ, Fuchs E. Myeloablative haploidentical bone marrow transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Blood 2011;118:abstract 4151.
78. Solomon SR, Sizemore CA, Sanacore M, Zhang X, Brown S, Holland HK, Morris LE, Bashey A. Haploidentical transplantation using T-cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012;18:1859-66.
79. Raj K, Streetly M, Kazmi M, Harringon E, Getzendaner LC, Lee SJ, O'Donnel PV. Peripheral blood progenitor cell (PBPC) transplantation from haploidentical donors following reduced intensity conditioning (RIC) for high-risk hematologic malignancies. Biol Blood Marrow Transplant. 2012; 18: S331 (abstract 343).
80. Aversa F. Haploidentical haematopoietic stem cell transplantation for acute leukaemia in adults: experience in Europe and United States. Bone Marrow Transplant 2008;41:473-81.
81. Klingebiel T, Cornish J, Labopin M, et al. Pediatric Diseases and Acute Leukemia Working Parties of the European Group for Blood and Marrow Transplantation (EBMT). Results and factors influencing outcome after fully haploidentical hematopoietic stem cell transplantation in children with very high-risk acute lymphoblastic leukemia: impact of center size: an analysis on behalf of the Acute Leukemia and Pediatric Disease Working Parties of the European Blood and Marrow Transplant group. Blood 2010;115:3437-46.
82. Castagna L, Bramanti S, Furst S, et al. Lower relapse and better PFS among chemosensitive patients undergoing allogeneic transplantation by haploidentical compared with HLA-identical DONOR: results on a cohort of 94 patients with Hodgkin's lymphoma. Blood 2013;122:abstract 2144.
83. Perruccio K, Tosti A, Burchielli E, et al. Transferring functional immune responses to pathogens after haploidentical haematopoietic transplantation. Blood 2005;106:4397-406.